1. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Issue 7 (July 2015) Authors: Mylam, Karen Juul; Kostakoglu, Lale; Hutchings, Martin; Coleman, Morton; Lamonica, Dominick; Czuczman, Myron S.; Diehl, Louis F.; Nielsen, Anne L.; Jensen, Paw; Loft, Annika; Hendel, Helle W.; Iyer, Victor; Leppä, Sirpa; Jyrkkiö, Sirkku; Holte, Harald; Eriksson, Mikael; Gillstrøm, Dorte; Hansen, ... Journal: Leukemia & lymphoma Issue: Volume 56:Issue 7(2015:Jul.) Page Start: 2005 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. (21st July 2022) Authors: Strati, Paolo; Coleman, Morton; Champion, Rebecca; Ma, Shuo; Patti, Caterina; Levy, Moshe Y.; Lossos, Izidore S.; Geethakumari, Praveen Ramakrishnan; Lam, Selay; Calvo, Roser; Higgins, Kara; Budde, Lihua E. Journal: British journal of haematology Issue: Volume 199:Number 1(2022) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biosimilars: Extrapolating the evidence. A roundtable discussion. Issue 2 (December 2015) Authors: Monk, Bradley J.; Coleman, Morton; Lammers, Philip; Somlo, George Journal: EJC supplements Issue: Volume 13:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. Issue 12 (4th September 2021) Authors: Forsberg, Peter A.; Rossi, Adriana C.; Boyer, Angelique; Pearse, Roger N.; Pekle, Karen A.; Jayabalan, David; Lakritz, Stephanie; Flicker, Kari; Ribadeneyra, Drew; Liotta, Brielle; Ely, Scott; Boussi, Leora; Allan, John N.; Coleman, Morton; Niesvizky, Ruben; Mark, Tomer M. Journal: American journal of hematology Issue: Volume 96:Issue 12(2021) Page Start: 1554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Characterization of ibrutinib‐sensitive and ‐resistant mantle lymphoma cells. (24th June 2014) Authors: Ma, Jiao; Lu, Pin; Guo, Ailin; Cheng, Shuhua; Zong, Hongliang; Martin, Peter; Coleman, Morton; Wang, Y. Lynn Journal: British journal of haematology Issue: Volume 166:Number 6(2014:Sep.) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Issue 10 (3rd October 2015) Authors: Reiss, Jonathan; Link, Brian; Ruan, Jia; Furman, Richard; Coleman, Morton; Leonard, John; Martin, Peter Journal: Leukemia & lymphoma Issue: Volume 56:Issue 10(2015:Oct.) Page Start: 2870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Issue 1 (January 2017) Authors: Furman, Richard R; Eradat, Herbert A; DiRienzo, Christine G; Hofmeister, Craig C; Hayman, Suzanne R; Leonard, John P; Coleman, Morton; Advani, Ranjana; Chanan-Khan, Asher; Switzky, Julie; Liao, Qiming M; Shah, Damini; Jewell, Roxanne C; Lisby, Steen; Lin, Thomas S Journal: Lancet Issue: Volume 4:Issue 1(2017) Page Start: e24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Issue 2 (February 2015) Authors: Elstrom, Rebecca L.; Ruan, Jia; Christos, Paul J.; Martin, Peter; Lebovic, Daniel; Osborne, Joseph; Goldsmith, Stanley; Greenberg, June; Furman, Richard R.; Avram, Anca; Putman, Ryan; Chapman, Erica; Mazumdar, Madhu; Griffith, Kent; Coleman, Morton; Leonard, John P.; Kaminski, Mark S. Journal: Leukemia & lymphoma Issue: Volume 56:Issue 2(2015:Feb.) Page Start: 342 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Issue 2 (28th January 2021) Authors: Coleman, Morton; Belada, David; Casasnovas, René-Olivier; Gressin, Rémy; Lee, Hui-Peng; Mehta, Amitkumar; Munoz, Javier; Verhoef, Gregor; Corrado, Claudia; DeMarini, Douglas J.; Zhao, Wanying; Li, Jia; Fay, Keith Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Issue 11 (2nd November 2015) Authors: Martin, Peter; Furman, Richard R.; Rutherford, Sarah; Ruan, Jia; Ely, Scott; Greenberg, June; Coleman, Morton; Goldsmith, Stanley J.; Leonard, John P. Journal: Leukemia & lymphoma Issue: Volume 56:Issue 11(2015:Nov.) Page Start: 3065 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗